Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 19/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733916 | 1.00 | DUT (0.49) | DUTKEAP1NFE2L2 | |
| SCHEMBL21733919 | 0.90 | DUT (0.61) | DUT | |
| SCHEMBL21733920 | 0.90 | DUT (0.61) | DUT | |
| SCHEMBL20188145 | 0.87 | DUT (0.57) | DUT | |
| SCHEMBL20188143 | 0.87 | DUT (0.57) | DUT | |
| SCHEMBL20190403 | 0.83 | DUT (0.52) | DUT | |
| SCHEMBL18374366 | 0.83 | DUT (0.48) | DUTKEAP1NFE2L2 | |
| SCHEMBL20188320 | 0.83 | DUT (0.59) | DUT | |
| SCHEMBL20190402 | 0.83 | DUT (0.52) | DUT | |
| SCHEMBL20338499 | 0.81 | DUT (0.50) | DUTKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570098-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570098-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | DUT 1/4885KEAP1 3873/4885NFE2L2 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.